Vaxcyte, Inc. (PCVX) Tuesday reported positive topline data from the Phase 1/2 study evaluating VAX-31, the Company's 31-valent pneumococcal conjugate vaccine (PCV) candidate to prevent invasive pneumococcal disease (IPD), in adults aged 50 and older.
In the Phase 1/2 study, VAX-31 was observed to be well tolerated and showed a safety profile at all doses studied through the full six-month evaluation period. Further, VAX-31 showed robust opsonophagocytic activity (OPA) immune responses for all 31 serotypes at all doses studied.
The company plans to initiate a Phase 3 study of VAX-31 by mid-2025 and announce topline data in 2026.
Vaxcyte also plans to initiate VAX-31 infant Phase 2 Study in the first quarter of 2025.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.